Skip to Main Content

Please be wary of fraudsters who may attempt to impersonate Cambridge Associates employees. Recently, reports have increased of scams that start with unsolicited invitations to join WhatsApp groups for sharing investment strategies or “stock tips.” Cambridge Associates does not participate in such activities. Avoid sharing personal details or conducting sales with unverified individuals. Report incidents to local authorities and the website owner. WhatsApp scammers may be reported here. For additional information, click here.

Sir John Bell

President and Co-CEO of Ellison Institute of Technology

Prof Sir John Bell leads multi-disciplinary teams at EIT Oxford – a major new interdisciplinary research and development facility that will support EIT’s mission to develop and deploy technology in pursuit of solving humanity’s most challenging and enduring problems.

Sir John served as Regius Professor of Medicine at the University of Oxford from 2002 to 2024. His extensive research interests span the areas of autoimmune disease, immunology and genetics. He was crucial in creating Genomics England, UK Biobank and Our Future Health. He has advised multiple Ministers and Prime Ministers in the UK government.

He was President of the Academy of Medical Sciences from 2006 to 2011 and elected Fellow of the Royal Society and honorary Fellow of the Royal Academy of Engineering.

Holder of prominent roles during the Covid epidemic, enabling the development of the testing platforms for lateral flow tests and helping to initiate the molecular testing program nationally, Prof Bell played a major role in the development and roll out of the Oxford-AstraZeneca Covid-19 vaccine.

He was appointed Knight Grand Cross of the Order of the British Empire (GBE) in the 2015 New Year Honours for services to medicine, medical research and the life science industry. He was appointed Companion of Honour (CH) in 2023 for services to medicine, medical research, the life science industry and public health.

This website is directed and intended to be accessed by persons who satisfy any of the following criteria:

  1. A professional client or an eligible counterparty*
  2. A financial advisor or financial intermediary acting on behalf of a professional client or eligible counterparty*
  3. An employee or prospective employee

If you satisfy any of these criteria, please click confirm to proceed:

Please check this box to remember my choice

*As defined in the Markets in Financial Instruments Directive (Directive 2014/65/EC) as amended or updated (MiFID)

This website is directed and intended to be accessed by persons who satisfy any of the following criteria:

  1. A regulated financial entity*
  2. An institutional investor, investment professional and other entities or individuals who are qualified to operate in financial markets involving regulated financial activity as defined by its local country regulator
  3. An employee or prospective employee

If you satisfy any of these criteria, please click confirm to proceed:

Please check this box to remember my choice

*An entity regulated by its local country regulator which may include banks, collective investment schemes, endowments, foundations, investment managers, insurance companies, pension funds and intermediaries

The information contained herein is not suitable for retail investors.

Please contact us if you have any questions: ContactCA@cambridgeassociates.com

If you clicked decline in error, please click here